SEQUANA MEDICAL NV (SEQUA.BR) Stock Price, Forecast & Analysis
Europe - EBR:SEQUA - BE0974340722 - Common Stock
SEQUA.BR Key Statistics, Chart & Performance
The current stock price of SEQUA.BR is 0.632 EUR. In the past month the price decreased by -17.17%. In the past year, price decreased by -23.3%.
SEQUA.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.33 | 105.58B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 23.09 | 49.49B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 17.22 | 23.87B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 17.21 | 23.86B | ||
| BIM.PA | BIOMERIEUX | 27.88 | 12.74B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 24.96 | 3.82B | ||
| DIA.MI | DIASORIN SPA | 16.98 | 3.30B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.62 | 1.29B | ||
| DRW8.DE | DRAEGERWERK AG | 9.49 | 1.15B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 27.58 | 1.03B | ||
| ELN.MI | EL.EN. SPA | 17.16 | 880.93M | ||
| GVS.MI | GVS SPA | 48.11 | 819.15M |
Related stock screener links
About SEQUA.BR
Company Profile
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
Company Info
SEQUANA MEDICAL NV
Kortrijksesteenweg 1112, Sint-Denijs-Westrem
Ghent OOST-VLAANDEREN BE
Employees: 48
Phone: 3292928065.0
SEQUANA MEDICAL NV / SEQUA.BR FAQ
What does SEQUA do?
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
What is the stock price of SEQUANA MEDICAL NV today?
The current stock price of SEQUA.BR is 0.632 EUR. The price decreased by -2.02% in the last trading session.
Does SEQUANA MEDICAL NV pay dividends?
SEQUA.BR does not pay a dividend.
What is the ChartMill technical and fundamental rating of SEQUA stock?
SEQUA.BR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting SEQUA stock to perform?
10 analysts have analysed SEQUA.BR and the average price target is 3.57 EUR. This implies a price increase of 464.87% is expected in the next year compared to the current price of 0.632.
Can you provide the market cap for SEQUANA MEDICAL NV?
SEQUANA MEDICAL NV (SEQUA.BR) has a market capitalization of 41.56M EUR. This makes SEQUA.BR a Nano Cap stock.
SEQUA.BR Technical Analysis
SEQUA.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SEQUA.BR. SEQUA.BR may be in some trouble as it scores bad on both profitability and health.
SEQUA.BR Financial Highlights
Over the last trailing twelve months SEQUA.BR reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS decreased by -31.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -346.67% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SEQUA.BR Forecast & Estimates
10 analysts have analysed SEQUA.BR and the average price target is 3.57 EUR. This implies a price increase of 464.87% is expected in the next year compared to the current price of 0.632.
For the next year, analysts expect an EPS growth of 65.31% and a revenue growth 684.31% for SEQUA.BR